- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00767949
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
April 13, 2012 updated by: Lpath, Inc.
A Phase 1, Dose-Escalating, Multi-Center, Study of iSONEP (Sonepcizumab [LT1009]) Administered as an Intravitreal Injection to Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is a disease that, in time, destroys the macula, which is the central part of the retina that gives sharp central vision.
The primary purpose of this study is to assess the safety of iSONEP which is a humanized monoclonal antibody against a bioactive lipid, sphingosine 1-phosphate (S1P).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
S1P modulates the AMD-associated processes of angiogenesis, inflammation and fibrosis.
A potential strategy for treating choroidal neovascularization associated with AMD is to reduce the biologically available extracellular levels of S1P.
iSONEP is highly selective for S1P and binds with picomolar affinity.
Lpath proposes that iSONEP would deprive many cell types (fibroblasts, pericytes, vascular endothelial cells and inflammatory) of important growth and survival factors thus targeting the multiple maladaptive processes of exudative AMD that ultimately result in the loss of photoreceptors, their supporting cells, and visual acuity.
Targeting simultaneously multiple components of the choroidal neovascular response is a novel approach and has the potential to be more potent than "single-targeted" therapeutics such as anti-VEGF therapies.
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85014
- Retinal Consultants of Arizona, LTD
-
-
Florida
-
Winter Haven, Florida, United States, 33880
- Center for Retina and Macular Disease
-
-
Indiana
-
Indianapolis, Indiana, United States, 46280
- Midwest Eye Institute
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49525
- Vitreo-Retinal Consultants
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Wills Eye Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 50 years and older
- BCVA ETDRS letter score in study eye between 20-57 letters using ETDRS refraction (Snellen of 20/70-20/400)
- Any CNV secondary to AMD in study eye, classic, minimally classic or occult with leakage on fluorescein angiography and intraretinal or subretinal fluid on OCT
- Visual acuity in fellow eye must be 20/800 or better at 4 meters
- Able to read, understand and sign the consent form before entering into study
Exclusion Criteria:
- Ocular disease other than CNV that could compromise vision in study eye
- Systemic immunosuppressive medication/therapy (e.g., chemotherapy, steroids)
- Uncontrolled hypertension and/or arrhythmias
- QT/QTc interval measurement >450 msec
- Cancer within the last 2 years except superficial basal or squamous cell skin cancer or cervical carcinoma in situ
- Have angioid streaks, presumed ocular histoplasmosis syndrome, myopia (>8 diopters) or CNV secondary to other causes than AMD
- Any additional ocular diseases which have irreversibly compromised visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema and severe non-proliferative diabetic retinopathy
- Any intraocular or general surgery, including cataract surgery, within 2 months of Day 1
- History of uveitis in either eye
- Any ocular or periocular infection within 4 weeks prior to Day 1
- Active ocular inflammation grade trace and above
- Cup to disc ratio >0.8, IOP >21 mmHg in glaucoma subjects treated with more than 2 ocular hypotensive agents
- Previous pars plana vitrectomy or trabeculectomy in study eye
- History of anterior vitrectomy
- Inability to obtain photographs, FA or OCT to document CNV, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access
- Aphakia
- Previous intravitreal Macugen, Avastin or Lucentis (injection or drug device implantation) in study eye within 6 weeks or triamcinolone within 6 months
- Receiving or requiring chronic concomitant therapy with systemic anti-angiogenic treatments p.o., parenteral (excluding inhaled steroids) (>5 mg) or topical corticosteroids in the study eye
- PDT within 12 weeks prior to Day 1
- Subjects taking systemic anticoagulants such as warfarin
- Investigational agents or devices within 6 weeks prior to Day 1
- Females who are pregnant or nursing and women of child bearing potential who are not using adequate contraceptive precautions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
iSONEP
|
single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine safety, tolerability, maximum tolerated dose and dose-limiting toxicity of iSONEP following a single intravitreal injection to subjects with choroidal neovascularization secondary to AMD
Time Frame: Active phase: 30 days post-injection; Follow-up phase: 12 months post-injection
|
Active phase: 30 days post-injection; Follow-up phase: 12 months post-injection
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To characterize systemic pharmacokinetics, evaluate the immunogenicity, and investigate preliminary efficacy on retinal lesion thickness determined by OCT; size and extent of CNV and lesion area; and visual acuity
Time Frame: Active phase: 30 days post-injection; Follow-up phase: 12 months post-injection
|
Active phase: 30 days post-injection; Follow-up phase: 12 months post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Glenn Stoller, MD, Lpath, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006 Mar;9(3):225-38. doi: 10.1016/j.ccr.2006.02.023.
- Caballero S, Swaney J, Moreno K, Afzal A, Kielczewski J, Stoller G, Cavalli A, Garland W, Hansen G, Sabbadini R, Grant MB. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res. 2009 Mar;88(3):367-77. doi: 10.1016/j.exer.2008.07.012. Epub 2008 Aug 6.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
July 1, 2010
Study Completion (Anticipated)
August 1, 2012
Study Registration Dates
First Submitted
October 2, 2008
First Submitted That Met QC Criteria
October 6, 2008
First Posted (Estimate)
October 7, 2008
Study Record Updates
Last Update Posted (Estimate)
April 16, 2012
Last Update Submitted That Met QC Criteria
April 13, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT1009-Oph-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Iconic Therapeutics, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
Clinical Trials on iSONEP
-
Lpath, Inc.PfizerTerminated
-
Lpath, Inc.CompletedExudative Age-related Macular DegenerationUnited States